Hubei Jumpcan - Public Comps and Valuation Multiples

Hubei Jumpcan Overview

About Hubei Jumpcan

Hubei Jumpcan Pharmaceutical Co Ltd engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemicals based on Chinese traditional medicines, and Chinese medicine health products in China. It offers Chinese and Western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, and geriatric. The company also develops Chinese and western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis.

Founded

1997

HQ

Employees

5.2K+

Website

jumpcan.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$1.9B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Hubei Jumpcan Financials

Hubei Jumpcan has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Hubei Jumpcan achieved revenue of $1.3B and an EBITDA of $498M.

Hubei Jumpcan expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Hubei Jumpcan valuation multiples based on analyst estimates

Hubei Jumpcan P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$1.3B	n/a	XXX	XXX	XXX
Gross Profit	$875M	$1.0B	XXX	XXX	XXX
Gross Margin	66%	NaN%	XXX	XXX	XXX
EBITDA	$498M	n/a	XXX	XXX	XXX
EBITDA Margin	37%	NaN%	XXX	XXX	XXX
Net Profit	$237M	$299M	XXX	XXX	XXX
Net Margin	18%	NaN%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Hubei Jumpcan Stock Performance

As of April 18, 2025, Hubei Jumpcan's stock price is CNY 26 (or $4).

Hubei Jumpcan has current market cap of CNY 24.1B (or $3.3B), and EV of CNY 13.6B (or $1.9B).

See Hubei Jumpcan trading valuation data

Hubei Jumpcan Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.9B	$3.3B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Hubei Jumpcan Valuation Multiples

As of April 18, 2025, Hubei Jumpcan has market cap of $3.3B and EV of $1.9B.

Hubei Jumpcan's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Hubei Jumpcan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Hubei Jumpcan and 10K+ public comps

Hubei Jumpcan Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$1.9B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	XXX	XXX
P/E	n/a	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Hubei Jumpcan Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Hubei Jumpcan Valuation Multiples

Hubei Jumpcan's NTM/LTM revenue growth is n/a

Hubei Jumpcan's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Hubei Jumpcan's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Hubei Jumpcan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Hubei Jumpcan and other 10K+ public comps

Hubei Jumpcan Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	n/a	XXX	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	$0.3M	XXX	XXX	XXX	XXX
Opex per Employee	$0.1M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	40%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	1%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	5%	XXX	XXX	XXX	XXX
Opex to Revenue	51%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry